EVEREST MED (01952) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.45 is considered Undervalued compared with the five-year average of 194.37. The fair price of EVEREST MED (01952) is between 35.14 to 60.95 according to relative valuation method. Compared to the current price of 33.88 USD , EVEREST MED By Undervalued By 3.59%.

Relative Value

Fair Zone

35.14-60.95

Current Price：33.88

3.59%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is EVEREST MED (01952) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

EVEREST MED (01952) has a current Price-to-Book (P/B) ratio of 2.97. Compared to its 3-year average P/B ratio of 2.10, the current P/B ratio is approximately 41.77% higher. Relative to its 5-year average P/B ratio of 1.80, the current P/B ratio is about 65.22% higher. EVEREST MED (01952) has a Forward Free Cash Flow (FCF) yield of approximately -4.06%. Compared to its 3-year average FCF yield of -9.27%, the current FCF yield is approximately -56.23% lower. Relative to its 5-year average FCF yield of -13.33%, the current FCF yield is about -69.57% lower.

Performance Decomposition

AI Analysis

Market capitalization of 01952 increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of 01952 in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is 01952 currently overvalued or undervalued?

What is EVEREST MED (01952) fair value?

01952's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of EVEREST MED (01952) is between 35.14 to 60.95 according to relative valuation method.

How does 01952's valuation metrics compare to the industry average?

The average P/S ratio for 01952's competitors is 0.00, providing a benchmark for relative valuation. EVEREST MED Corp (01952) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for EVEREST MED (01952) as of Mar 03 2026?

As of Mar 03 2026, EVEREST MED (01952) has a P/B ratio of 2.97. This indicates that the market values 01952 at 2.97 times its book value.

What is the current FCF Yield for EVEREST MED (01952) as of Mar 03 2026?

As of Mar 03 2026, EVEREST MED (01952) has a FCF Yield of -4.06%. This means that for every dollar of EVEREST MED's market capitalization, the company generates -4.06 cents in free cash flow.

What is the current Forward P/E ratio for EVEREST MED (01952) as of Mar 03 2026?

As of Mar 03 2026, EVEREST MED (01952) has a Forward P/E ratio of 512.01. This means the market is willing to pay $512.01 for every dollar of EVEREST MED's expected earnings over the next 12 months.

What is the current Forward P/S ratio for EVEREST MED (01952) as of Mar 03 2026?

As of Mar 03 2026, EVEREST MED (01952) has a Forward P/S ratio of 5.45. This means the market is valuing 01952 at $5.45 for every dollar of expected revenue over the next 12 months.

01952 Valuation